Vizuro and DCB Join Forces to Revolutionize Drug Discovery and Precision Medicine with Causal Generative AI
Summary
This collaboration aims to establish a next-generation AI computational platform, advancing breakthroughs in drug discovery and accelerating the implementation of precision medicine. Supported by the Department of Industrial Technology, Ministry of Economic Affairs R.O.C, DCB has been focusing on cancer drug development, precision medicine, and innovative therapies. By combining their unique expertise, Vizuro and DCB aim to create next-generation biotech products and platforms, driving progress in both research and commercial ventures. By combining DCBs extensive expertise in drug development and startup incubation with Vizuros capabilities in causal and generative AI technology, this collaboration represents a powerful synergy. Its expertise lies in combining deep learning and causal inference to identify biological targets and simulate drug designs from multimodal data.